home / stock / ymtx / ymtx news

YMTX News and Press, Yumanity Therapeutics Inc. From 06/06/22

Stock Information
Company Name: Yumanity Therapeutics Inc.
Stock Symbol: YMTX
Market: NASDAQ
Menu
YMTX YMTX Quote YMTX Short YMTX News YMTX Articles YMTX Message Board
Get YMTX Alerts

News, Short Squeeze, Breakout and More Instantly...
YMTX - Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions

Yumanity Therapeutics, Inc. to sell its clinical-stage product candidate YTX-7739 as well as its unpartnered discovery-stage neuroscience product candidates and targets to Janssen Pharmaceutica NV in a $26 million cash transaction Kineta, Inc., a private immuno-oncology company,...
YMTX - Turning Point, Amylyx top healthcare gainers; Novavax, Rallybio lead losers' pack

Gainers: Turning Point Therapeutics (TPTX) +116%. Amylyx Pharmaceuticals (AMLX) +27%. Yumanity Therapeutics (YMTX) +11%. Amarin (AMRN) +9%. Galecto (GLTO) +8%. Losers: Novavax (NVAX) -13%. Rallybio (RLYB) -13%. Invitae (NVTA) -9%. Spruce Bioscience...

YMTX - Immix, Bright Green top healthcare gainers; while Zosano, Immunic lead losers' pack

Gainers: Immix Biopharma (IMMX) +37%. Bright Green (BGXX) +29%. Repare Therapeutics (RPTX) +29%. Yumanity Therapeutics (YMTX) +24%. PDS Biotechnology (PDSB) +15%. Losers: Zosano Pharma (ZSAN) -48%. Immunic (IMUX) -41%. Aeglea BioTherapeutics (AGLE) -40%...

YMTX - Yumanity Therapeutics GAAP EPS of -$1.24, revenue of $1.02M

Yumanity Therapeutics press release (NASDAQ:YMTX): Q1 GAAP EPS of -$1.24. Collaboration revenue of $1.02M. For further details see: Yumanity Therapeutics GAAP EPS of -$1.24, revenue of $1.02M

YMTX - Yumanity Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Developments

BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced financial results for the first ...

YMTX - Clever Leaves, Tilray top healthcare gainers; MEI Pharma, Icosavax lead losers' pack

Gainers: Clever Leaves (CLVR) +28%. Tilray Brands (TLRY) +13%. Cutera (CUTR) +11%. STRATA Skin Sciences (SSKN) +10%. Clarus Therapeutics (CRXT) +8%. Losers: MEI Pharma (MEIP) -58%. Icosavax (ICVX) -50%. Rezolute (RZLT) -9%. Alpha Tau Medical (...

YMTX - Yumanity Therapeutics GAAP EPS of -$3.84, revenue of $8.04M

Yumanity Therapeutics press release (NASDAQ:YMTX): FY GAAP EPS of -$3.84. Collaboration Revenue of $8.04M (+16.5% Y/Y). As of December 31, 2021, cash, cash equivalents and investments were $36.5 million. For further details see: Yumanity Therapeutics GAAP EPS of -$3.84, revenue of ...
YMTX - Yumanity Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Developments

BOSTON, March 24, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced financial results for full-yea...

YMTX - Creative Medical, 4D pharma top healthcare gainers; Cue Health, Codex take losers' tag

Gainers: Creative Medical Technology CELZ +99%. 4D pharma LBPS +87%. Femasys FEMY +21%. Revelation Biosciences (REVB) +19%. NeuroSense Therapeutics (NRSN) +7%. Losers: Cue Health (HLTH) -17%. Codex DNA (DNAY) -17%. PetVivo (PETV) -14%. Yumanity The...

YMTX - YMTX, YQ and VLON among mid-day movers

Gainers: NeuroSense (NRSN) +333%. BitNile (NILE) +69%. Yumanity Therapeutics (YMTX) +50%. BT Brands (BTBD) +41%. Mullen Automotive (MULN) +39%. Hudson Capital (HUSN) +38%. O2Micro International (OIIM) +32%. Cenntro Electric Group (CENN) +33%. Akanda (AKAN) +29%. Anaplan (PLAN) +28%. Losers: V...
Previous 10 Next 10